# CytoMed Therapeutics Limited (GDTC)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001873093 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001873093))
- Full page: https://inspectstocks.com/stocks/gdtc
- Data as of: price 2026-09-29; newest filing used 2026-03-31; latest fiscal period ended 2025-12-31

## Grade

**D-** on the growth-and-cash rubric, 1 of 4 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | not answerable |  |  |
| Revenue growing recently | passed |  |  |
| Free cash flow positive | failed |  |  |
| Free cash flow growing overall | failed |  |  |
| Free cash flow growing recently | failed |  |  |

Business quality (the + / − mark): 1 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed |  |  |
| Healthy profit margin | failed |  |  |
| Good return on equity | failed |  |  |
| Debt under control | passed |  |  |
| Turns sales into cash | failed |  |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, converted from SGD at today's spot rate (every period alike).

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $253.9K |
| Net income, trailing twelve months | -$3.1M |
| Free cash flow, trailing twelve months | -$3.4M |
| Net margin | -1,227.1% |
| Return on equity | -60.8% |
| Debt to equity | 0.07 |
| Diluted EPS, trailing twelve months | -$0.27 |
| Share price | $0.83 |
| Market value | $9.8M |
| Price / sales | 38.4x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/gdtc)
- [Financial statements](https://inspectstocks.com/stocks/gdtc/financials)
- [Competitors](https://inspectstocks.com/stocks/gdtc/peers)
- [Earnings](https://inspectstocks.com/stocks/gdtc/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.